GSE211599
Transcription profiling of PfSPZ Malaria Vaccine trial subjects receiving a 3-dose regimen in a malaria endemic region
The Sanaria® PfSPZ Vaccine can confer sterilizing protection against liver stage infection by Plasmodium falciparum (Pf) in malaria naïve individuals. The vaccine consists of aseptically purified irradiated Pf sporozoites. Vaccinees received 3 doses of 1.8 X 106 irradiated sporozoites. Efficacy was measured by challenged by controlled human malaria infections (CHMI),  and against naturally occurring Pf Infections in Malian adults during the malaria transmission season Overall design: 32 samples from 2 time points, pre-vaccination (Day -7) and post-vaccination (Day 116), for 16 Malian adult participants who all received 3 doses of the PfSPZ vaccine. All subjects remained uninfected after CHMI and 9 participants remained uninfected during the subsequent malaria season